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involving a bifurcation site, restenotic lesions (including in-stent restenosis). two-vessel 
disease (a maximum of 2 lesions located in 2 different epicardial vessels), long lesions 
(up to 53 mm). 
Methods: The primary endpoint of the study is the Target Lesion Revascularization 
(TLR) rate at 160 days after stent implantation. Secondary endpoints are Target Vessel 
Failure (TVF) at 160-days, Major Cardiac Events (MACE) at 30-days and 160-days, 
MACE at l-year, P-years and 3-years in a subset of 500 patients, device succsss, procs- 
dure success and resource utilization. 
Results: As of abstract submission, data about 1252 patients enrolled at 60 investiga- 
tional sites is available for analysis, for a total of 1435 lesions treated. Among these, 374 
(34%) ware restenotic lesions. 
Conclusions: The patient recruitment in the DELIVER II study was completed on gt” of 
September 2002. Thirty-day safety results from the restenotic lesions subgroup will be 
available for presentation .and will be compared with the outcome of other lesion sub- 
groups. Multivariate analysis combining restenosis with other complicating factors will be 
presented as well. 
* Manufactured by Cook Incorporated. DELIVER II is conducted by Guidant Corporation 
on behalf of Cook Incorporated. 
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Background: Rapamycin, a maciolide antibiotic, inhibits SMC proliferation in vitro and in 
viva by blocking cell cycle progression at the GlIS transition. Given the anti-proliferative 
and anti-migratory properties of rapamycin, it may have anti-restenosis properties after 
PTCA and placement of coronary stsnts. Recently, implantation of rapamycin (sirolimus) 
eluting stems in de now lesions was shown to be safe and effective in inhibiting neointi- 
mal formation. The safety and efficacy of oral rapamycin in reducing the incidence of inti- 
mal hyperplasia and restsnosis is not known. 
Methods: Thirty Patients with stable exertional angina will receive standard therapy 
(ASA + Clopidegrol) plus rapamycin (loading dose 6 mg on the day of the procedure, fol- 
lowed by 2 mg/day) for either 2 (phase 1, n=15) or 4 (phase II, n=15) weeks after stent 
implantation for denovo lesions. Blood will be obtained for rapamycin levels, CBC, renal 
function and lipid profile. Quantitative coronary angiography @CA) and IVUS imaging 
will be performed immediately after the procedure and at a 6 month follow-up in all 
patients for evaluation of the primary endpoint of neointimal volume and binary resteno- 
sis. Results: To date, 15 (completed study-phase one) patients (mean age 60*10. 70% 
males, 27% diabetics, 40% prior MI) have been enrolled. All patients tolerated the load- 
ing dose plus two week course of oral Rapamycin without any significant side effects or 
laboratory abnormalities. There was one episode of recurrent in-hospital ischemia (few 
hours after the procedure) for suboptimal angiographic result which required further 
stenting. Angiographic and IVUS follow-up is in progress and will be presented for these 
patients as well as the full safety data on all 30 patients. 
1198-183 Oral Rapamune to Inhibit Restenosis in Patients With 
Multi De-Novo Coronary Lesions Requiring Stenting 
Ron Waksman, Andrew E. Ajani, August0 D. Pichard. Ellen Pinnow, Lowell F. Satler. 
Kenneth M. Kent, Neil J. Weissman, Rebecca Torguson, Louise Gambone, Maureen 
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Background: Drug-eluting stents (utilizing antiproliferative agents such as Rapamune) 
have shown the ability to limit restenosis. Oral Rapamune (R) is an alternative delivery 
strategy that can target multi-stenosed coronary vessels and may potentially lower the 
cost and vessel toxicity. 
Methods: The Cal Rapamune to Inhibit Restenosis (ORBIT) is an open label study of 
60 patients (pts) with de nova coronary artety stewsis treated with stent implantation in 
up to 2 vessels. The first 30 pts received R 2 mg /day for 30 days, and the last 30 pts 
received R 5mgIday for 30 days. The loading dose for both regimens was 5 mg given 
either immediately prior to or after the intervention. Patients underwent clinical and 
angiographic follow-up. 
Results: In the first 30 patients who received R 2 mg/day (age 60 * 10 years, 66% 
males, 13.3% diabetes), the mean number of treated lesions par pt was 1.6 f 0.5, with a 
reference vessel diameter of 3.0 r 0.5 mm and mean lesion length of 19.7 * 9.0 mm. 
Angiographic success was achieved in all pts. Mean pre-discharge serum R levels were 
5.1 f 3.1 ng/ml and at 30 days 6.5 + 4.2 (17 pts). Drug therapy was discontinued in 3 pts 
from the 2 mg group and in 5 pts from the 5 mg group due to skin rash, diarrhea, mouth 
ulcers, or fatigue (or a combination of these symptoms). There were no biological or bio- 
chemical adverse affects. 
In the 2 mg group, 49 lesions were treated. Of these, 40 were available for angiographic 
follow-up. The binary restenosis for in-stent was 5.0% and for in-segment was 7.5%. The 
late loss in-stent was 0.62 f 0.61 and the in-segment was 0.29 f 0.52 mm. Target lesion 
and vessel revascularization was 15.6%. Conclusions: Oral Rapamune administration 
for the prevention of restenosis is safe and feasible. Low rates of restenosis and late loss 
were observed with a dose of 2 mgiday. Complete g-month follow-up for the R 5mgld 
group will be available at presentation. 
1198-164 Stent Release of a Rapamycin Analogue: Tissue 
Pharmacoklnetics of Rapid Versus Delayed Release 
Frederick G. Walt, Elazer R. Edelman, Neda Vukmirovic, Campbell Rogers, Harvard- 
MIT, Cambridge, MA, Brigham and Woman’s Hospital, Boston, MA 
Bsckground:The effect of drug release rates from stents on tissue uptake and biologic 
effect are poorly understood. We investigated tissue distribution under varied release 
conditions of a stent-delivered rapamycin analogue. Methods and Resultsd6 rabbits 
underwent iliac artery stenting with a stent coated with a phospholylcholine polymer 
loaded with 3H drug (100 ).&tent). We compared 2 formulations: formulation l- rapid 
release, and formulation 2- slow release. Animals were harvested at 1. 3. 7, 14, and 28 
days and stent and tissue drug concentration determined through liquid scintillation 
counting. In viva drug release from formulation 1 was >90% at 3 days. Release from for- 
mulation 2 did not reach >90% until 14 days(P=0.005 by ANOVA). Arterial deposition 
peaked at 1 day with formulation 1 (726.0+154.3 pg/g tissue) and at 3 days in formulation 
2 (1339.0*412.6 pglg tissue). When plotted against percent of drug released from stew. 
efficiency of deposition (pg drug/g tissue/pg drug released) from formulation 2 was best 
fit by a polynomial equation (R* 0.64, p<O.OOl) and was greater (p=O.O4 by ANOVA) than 
efficiency from formulation 1 which was best fit by a linear equation (R2 0.56, 
p<O.OOl)(Figure). Conclusion: Delayed release enhances the efficiency of delivery of a 
rapamycin analogue to tha vessel wall. Modulating release may offer a more effective 
method of enhancing stent-based drug delivery than increasing dose. 
1198-l 85 Can Sirolimus-Elutlng Stents Tolerate Some Degree of 
Geographic Miss? 
Cherukupalli Raahu, Yves Louvard, Marie-Claude Morice, Carlo di Mario, Martin Leon, 
Jeffrey Moses, Judith Jaeger, Josef Ludwig, David Holmes, Antonio Colombo, lnstitut 
Cardiovasculaire Paris Sud, Massy, France, Centro Cuore Columbus, Milan, Italy 
Background. Sirolimus-eluting stems have proven their ability to almost completely sup- 
press 6.month neointimal proliferation in the stented segment. However, linls is known 
on the efficacy in the segments adjacent to the stent, dilated but not stented. 
Methods and Results. In a multicenter randomised bifurcation trial, between June 2001 
and April 2002, 66 pts with a significant stenosis at a bifurcation ware enrolled. The effi- 
cacy of sirolimus-eluting stents in these lesions has been evaluated. Pts were ran- 
domised into 2 groups of 43 each to receive either 2 stents (main vessel and branch) or 1 
stent (main vessel only). At the operator’s discretion 22 patients in the single stent arm 
have crossed over to the 2 stent arm. Baseline characteristics were comparable in both 
groups: mean age 63etO years, males 60.2%, diabetes 22%, and unstable angina 
17.4%. 
By means of QCA, films of 47 pts were analyzed before and after Intervention and at 6- 
months for the presence of geographic miss and its effect on restenosis. 5 patients who 
had acute procedural failure ware excluded from the analysis. Geographic miss has been 
defined as any balloon inflation beyond the non-stented segment. The segments proxi- 
mal and distal to the stent in the main vessel as well as the side branch have been exam- 
ined for geographic miss. 
Conclusion. Even in the era of drug-eluting stems, the process of restenosis is multifac- 
torial and the presence of geographic miss does not seem to influence the restanosis 
rates in bifurcation lesions. 
Study Group Restenosis 
No geographic miss (17/42) 6 (35%) 
Geographic miss (25/42) 4 (16%) 
Main vessel (10) 
Proximal to stent(4) 0 
Distal to stent (6) 1 
Side branch(l9) 3 
1198-186 Association Between Progression of Untreated 
Coronary Lesions and In-Stent Restenosis 
Dirk Skowasch, Joachim Vaerst, Alexander Jabs, Rend AndriB, Berndt Liideritz, Gerhard 
Baurisdel University of Bonn, Bonn, Germany -. 
Background: Progression of coronary artery disease is not completely understood, nei- 
ther for de-now stenoses nor for in-stent restenosis (ISR) as accelerated arteriosclero- 
sis. The objective of this angiographic study was to assess an association between 
presence of ISR and the progression of untreated coronary lesions. 
Methods: A Series of 212 high-grade native coronary stenoses (mean stenotic degree 
66%) of 150 patients was treated by stent implantation; 129 additional lesions with mild 
to moderate stenoses (>30%) remained untreated. Quantitative coronary angiography 
analysis was performed after 6+2 months regarding ISR (stenosis >50%), coronary pro- 
gression (increase in stenosis >20%) and regression (decrease >20%), rasp. Angio- 
graphic, procedural and clinical characteristics were assessed for a possible association 
to ISR and/or coronary progression. 
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Results: ISR was seen in 83 of 212 (39%) stented lesions. Of predictive value were 
presence of diabetes mellitus (P~0.04) as well as cumulative time of inflations (P=O.Ol) 
as procedural determinants. Angiographic progression was found in 12 of 129 (9%) pri- 
marily untreated lesions. Progression of a normal segment or regression were not seen. 
Progression of native plaques was associated with presence of ISR in 11 cases and with 
absence of ISR in 1 case (P=O.Ol). Smoking (PcO.02) turned out predictive for plaque 
progression. whereas medication and procedural angiographic parameters did not. Nota- 
bly, 9 of 11 (82%) patients with progression presented with acute coronary syndromes at 
follow-up. 
Conclusion: The findings of the present pilot study show that restenosis of a target 
stenosis following stent implantation IS associated with progression of other untreated 
lesions, and thereby suggest that both arteriosclerosis forms share common systemic 
pathogemc mechanisms. With presence of ISR, angiography of primarily untreated coro- 
naries should be performed, especially in case of preexisting plaques. 
Gianturco coil). Moderate sized devices were used more frequently (1 patient recerved 
the 514 device; 2 the 614; 22 the 816; 7 the 1018; 3 the 12/10; 1 the 14112 and 1 patient 
received the 16114 mm device). Complete angiographic closure was seen immediately 
after device deployment in 29 out of 36 (81%) patients. At 24 hours, complete closure as 
evidenced by color Doppler echocardiography was demonstrated in 34 out of 36 (94%) 
patients. The remaining two patients had small residual shunt. At 6-month and l-year fol- 
low-up, complete closure was demonstrated in 35 out of 36 (97%) patients. In the two 
patients with small residual shunts at 24 hours post-procedure, one patient demonstrated 
complete closure by echocardiography at 6.months post-procedure. The other patient 
had no available follow-up. No complications related to device implantation occurred in 
any patient. 
Conclusions: Closure of PDA using the ADO is safe and effective in adult patients 
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1199-l 73 Results of U.S. Phase I Clinical Trial of Closure of 
Patent Foramen Ovale Associated With Stroke/ 
Transient lschemic Attack or Peripheral Embolism 
Using the Amplatzerfi Patent Foramen Ovale Device 
Tom Hong, Ziyad M. Hijazi, Donald J. Hagler, Hitendra Patel, John P. Cheatham. Lowell 
Satler, Richard Smalling, University of Chicago, Chicago, IL. Mayo Clinic, Rochester, MN 
Background: Patients with a patent foramen wale (PFO) and paradoxical embolism are 
at risk for recurrent thromboembolic events. We report the results of Phase 1 US clinical 
trial of patients who underwent transcatheter PFO closure for secondary prevention of 
paradoxical embolism using the AmplatzeK@ PFO occlude, (APO). 
Methods: From March 2000 through May 2002, 50 patients (28 males and 22 females) 
with PFO and at least 1 paradoxical embolic event were referred for transcatheter PFO 
closure using the APO. The median age was 41 yr. (range 15 - 61 yr.) and the median 
weight was 81 kg (range 45 - 118). Thlrty-six patients had cryptogenic stroke, 10 
patients had transient ischemic attack and 4 patients had peripheral embolism. Seven- 
teen patients had both a PFO and an atrial septal aneurysm. 
Results: Of 50 patients referred for closure, 49 underwent attempted closure of their PFO 
using the APO; one patient did not have a PFO. Fifty devices were successfully deployed 
I” all 49 patients (one patient received two devices for two separate fenestrations). 
Immediate complete closure es documented by transesophageal echocardiography 
(TEE)“no passage of bubbles from right to left atrium dunng Valsalva” was achieved in 
26/49 (53%) patrents and at 24 hours, by transthoracic echocardiography (TTE) was 
achieved in 31 (63%) patients. The median fluoroscopy time was 10.5 minutes (range 2.6 
- 43) and the median procedure time was 85.5 minutes (range 18 - 309). Complications 
encountered during and within the follow-up period included one patient who developed 
a hem&ma and an AV fist& requiring surgery and two patients who developed atrial 
fibrillation. At 3.month follow-up. 44 patients had a TrE with contrast bubble study, 38 
(86%) had complete closure. At a median follow-up interval of one year (range one 
month-569 days), there have been no recurrent embolic events. 
Conclusion: Transcatheter closure of PFO using the APO seems to be a safe and effec- 
twe therapy in the prevention of thromboembolic events in patients with a history of pre- 
sumed paradoxical embolism. 
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Background: Surgical closure of patent ductus arteriosus (PDA) in adult patients may be 
problematic. Recently, transcatheter closure of PDA using the Amplatzer duct occluder 
(ADO) has been shown to be safe and efficacious. We present our experience with this 
device in the adult population. 
Methods: Between January 2000 and January 2002, forty-one adult patients (31 females 
and 10 males) with a PDA were referred for closure with the ADO. The median age was 
35.8 years (range 18 - 70.7). The median Qp/Qs was 1.4 (range 0.6 - 3.5). The median 
diameter of the pulmonary artery end (narrowest diameter) was 3.4 mm (range 1.5 - 10); 
the median diameter of the ampulla was 10.7 mm (range 3.0 - 32) and the median length 
was 10.8 mm (range 1.5 - 35) According to the Toronto classification, there were 33 
Type A PDA’s; 1 Type B; 1 Type C; 2 Type D and 4 Type. 
Results: Of forty-one patients. thirty-seven underwent attempted closure of their PDA 
using the ADO. In the remaining four patients, the PDA was small, and was closed using 
Gianturco coils. The device was successfully deployed in all but one patient (the ductus 
could not be crossed and the patient ultimately had successful PDA closure using a 
Debabrata Mukheriee, Sujoya Dey, Prasanth Lingam, Stanley J. Chetcutl, Paul M 
Grossman, Mauro Moscucci, Sanjay Rajagopalan. Ann E. Luciano, Kim A. Eagle, 
University of Michigan, Ann Arbor, Ml 
BACKGROUND: Statins and anti-platelet therapy are beneficial in patients undergoing 
percutaneous coronary interventions. Minimal data exists on the effectiveness of statins 
and dual antiplatelet therapy in patients undergoing peripheral vascular interventions. 
METHODS: 79 patients underwent peripheral vascular interventions between Jan 2001- 
Feb 2002. Clinical, procedure, and out&me data were collected by use of a standardized 
form and follow-up by structured phone call > 6 months post-procedure. Multivariate 
logistic regression analysis was used to adjust for baseline characteristics and comorbid- 
ities and adjusted odds ratios were calculated for the composite of death, Ml and stroke 
at 6.months. 
RESULTS: Fourteen of the 79 patients (17.7 %) had one or more cllnical event (death, 
Ml or stroke). After adjustment for demographics and comorbidities, statin therapy 
(OR=0.21,95% Cl 0.05 - 0.86, p=O.O3) and clopidogrel therapy (OR=0.17, 95% Cl 0.04 - 
0.78, p=O.O2) were associated with a significant reduction of the composite event rate at 
6 months. 
CONCLUSIONS: In this study cohort of patients undergoing peripheral endovascular 
intervention, statin therapy and anti-platelet therapy with clopidogrel were each associ- 
ated with a significantly lower risk-adjusted cardiovascular event rate at six months fol- 
low-up. These preliminary findings offer logical targets for quality improvement. 
Multwariate predictors of major adverse cardiac events after penpheral mtervenfmns 
No event Event Adjusted Odds ratio (95% P 
(n=65) (ll=l4) Cl) V&C? 
Age 66.8* 10.1 69.5 * 11.4 1.02 (0.96-1.09) 0.41 
Serum 1.2 + 0.6 1.8 f 0.8 2.27 (0.86-5.66) 0.08 
creatinine 
Diabetes 29.6 % 35.7 % 1.80 (0.39-8.12) 0.40 
StatIn use 64.1 % 28.5 % 0.21 (0.05-0.86) 0.03’ 
Clopidogrel use 82.8 % 57.1 % 0.17 (0.04-0.78) 0.02’ 
1199-176 Stenting of Renal Artery Stenosis Preserves Renal 
Function in Both Diabetic and Nondiabetic Patients 
With Chronic Renal Insufficiency 
Rajesh Subramanian, Jose A. Silva, Stephen R. Ramee, Tyrone J. Collins, Stephen J. 
Jenkins, Christopher J. White, Ochsner Clinic Foundation, New Orleans, LA 
Background: Renal artery stenting has been shown to stabilize or improve renal function 
in a significant proportion of patients with atherosclerotic renovascular disease and 
impaired renal function. Whether diabetic (DM) patients obtain similar benefits as nondia- 
betic patients (NDM) is unknown. 
Methods: The renal function of 36 consecutive pabents wth bilateral renal artery 
stenoses (11 DM; 25 NDM) and renal insufficiency (serum creatinine >/= 1.5 mgidl) was 
analyzed by plotting the reciprocal of serum creatinine versus time in days before and 
after stenting. 
Results: All patients had deterioration of renal function prior to intervention. At 47.4 +I- 
31.2 months post intervention, renal function improved or did not change in 76% and 
worsened in 24% of NDM patients compared to 73% and 27% of DM patients respec- 
tively (p=NS). (Figure) 
Conclusion: Renal artery stenting is equally beneficial in DM and NDM patients with 
impaired renal function and atherosclerotic renal artery stenosis. 
